Gasec

Quick links to important sections

Gasec

Selected form

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Gasec

Property Description
Active ingredient Omeprazole
Form Gastro-resistant capsule (Delayed-release capsule)
Pharmacological class Proton pump inhibitor (PPI)
General purpose Sustained reduction of gastric acid secretion
Origin Synthetic benzimidazole derivative

The medicine Gasec is a commercial trade name associated with the active ingredient Omeprazole, which is identified pharmacologically as a synthetic compound designated an antisecretory compound. Omeprazole belongs to the highly specific class of Proton pump inhibitors (PPIs). This PPI classification is clinically recognized for providing effective control over the production of stomach acid. This distinct mechanism fundamentally differs from older acid-reducing agents by operating at the source of acid production.

Gasec Composition and Physical Form

Gasec is formulated as a single-ingredient product and is intended for oral administration. The active chemical substance, Omeprazole, is typically supplied in specialized dosage forms, most notably gastro-resistant capsules (or delayed-release capsules). This gastro-resistant design is critical because Omeprazole is highly sensitive to the stomach's acid. This formulation ensures the drug is protected until it is successfully delivered to the small intestine for absorption. Gasec is often positioned for managing acid reflux symptoms in adult patients.

General Purpose: Targeting Gastric Acid

The essential purpose of Omeprazole is the sustained reduction and inhibition of gastric acid secretion by targeting the proton pump enzyme system in the stomach lining. By achieving this profound acid suppression, the medicine generally helps to manage discomfort and symptoms driven by hyperacidity in the upper gastrointestinal tract. A typical use scenario involves mitigating recurring discomfort associated with acid indigestion by consistently lowering the acid load, which supports the environment necessary for the healing of tissues subjected to excessive acid exposure.

What side effects are possible with Gasec?

Possible Side Effects and Safety Information

The official safety profile for Gasec (Omeprazole) is structured by regulatory agencies to classify adverse reactions based on their estimated frequency and the body system affected. These classifications distinguish common, expected effects from rare, medically serious events, aligning with standards set by the EMA and FDA.


Frequency and System-Organ Classes

The adverse reactions are typically categorized using frequency bands (Common, Uncommon, Rare) and are organized by System-Organ-Classes (SOC), which include Gastrointestinal, Nervous system, Skin and subcutaneous tissue, and Blood and lymphatic system disorders.

Common adverse reactions officially listed in regulatory documents include headache and various gastrointestinal effects such as abdominal pain, diarrhea, constipation, flatulence, nausea, and vomiting.


Serious Adverse Reactions and Duration-Related Safety

Regulatory labels document serious adverse reactions that occur rarely, including severe hypersensitivity responses like anaphylactic shock and severe skin conditions such as Stevens-Johnson syndrome (SJS). There is also an increased risk of certain infections, such as Clostridium difficile-associated diarrhea (CDAD), officially noted with Omeprazole treatment.

Safety statements in regulatory documentation highlight effects associated with exposure duration. Long-term and high-dose use is officially noted as being associated with a possible increased risk of osteoporosis-related fractures (hip, wrist, or spine) and may lead to the formation of benign fundic gland polyps. Specific safety constraints apply to individuals with severe hepatic impairment, where dose adjustments may be necessary due to altered drug metabolism.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information describes the documented manifestations and required emergency actions for Gasec (Omeprazole) overdose.

Documented Overdose Presentations

Property Official Regulatory Statement
Documented overdose presentations Manifestations reported in human overdose cases include transient symptoms such as confusion, drowsiness, headache, nausea, vomiting, abdominal pain, diarrhea, tachycardia (fast heart rate), blurred vision, flushing, dry mouth, and increased sweating.
Physiological systems affected Symptoms reported affect the central nervous system, cardiovascular system, and gastrointestinal system.
Dose-related or exposure factors Overdose cases have been reported with doses substantially exceeding the usual daily therapeutic dose, up to 2400 mg.

Emergency Response and Management

Classification Property Official Regulatory Statement
Severity classification Symptoms observed in overdose are generally classified as mild-to-moderate and reversible, with no serious clinical outcomes consistently documented as a defining feature.
Antidote Status No specific antidote is known for omeprazole overdose.
Emergency-response statement Get medical help or contact a Poison Control Center right away if overdose is suspected. Hospital observation is necessary for monitoring and managing symptoms.

Official overdose statements:

  • Patients are required to seek immediate medical attention upon suspected overdose.
  • Treatment for omeprazole overdose is symptomatic and supportive.
  • The substance is not readily dialyzable due to its high plasma protein binding.

Connection to the Overall Overdose Profile

Regulatory documents define the omeprazole overdose profile by listing a spectrum of generally mild and transient clinical manifestations and explicitly stating that no specific antidote is known. This framework mandates that, while symptoms are typically reversible, immediate medical attention is required to ensure stabilization and provide necessary supportive care as per official guidance.

Therapeutic Uses of Gasec

Main Uses of Gasec

Gasec contains omeprazole, a medication classified as a proton pump inhibitor (PPI). It is primarily used to manage conditions caused by excessive stomach acid production. By reducing the amount of acid secreted by the stomach lining, it allows the digestive tract to heal and prevents further irritation.

Gastroesophageal Reflux Disease (GERD)

This medication is used to treat gastroesophageal reflux disease, a condition where stomach acid flows back into the esophagus. This backward flow can cause heartburn and an unpleasant sour taste in the mouth. Gasec helps alleviate these symptoms and aids in the healing of erosive esophagitis, which is inflammation or damage to the esophageal lining caused by chronic acid exposure.

Peptic Ulcers

Gasec is indicated for the treatment and prevention of ulcers in the stomach (gastric ulcers) and the upper part of the small intestine (duodenal ulcers). It creates an environment with lower acidity, which is necessary for these sores to heal. Additionally, it may be used to prevent the formation of ulcers in patients who require long-term treatment with non-steroidal anti-inflammatory drugs (NSAIDs).

Helicobacter pylori Eradication

In cases where ulcers are associated with an infection by the bacterium Helicobacter pylori, Gasec is used as part of a combination therapy. While the medication does not kill the bacteria itself, it reduces stomach acid to help antibiotics work more effectively and to allow the ulcer to heal.

Hypersecretory Conditions

The medication is used to manage rare conditions where the stomach produces abnormally high levels of acid, such as Zollinger-Ellison syndrome.

Benefits of Treatment

  • Symptom Relief: Significant reduction in the frequency and severity of heartburn, acid regurgitation, and stomach pain.
  • Tissue Healing: Promotes the repair of the mucous membranes in the esophagus, stomach, and duodenum.
  • Prevention of Complications: By managing acid levels, the medication helps reduce the risk of more serious issues, such as gastrointestinal bleeding or strictures (narrowing) of the esophagus.
  • Prophylactic Protection: Offers protection for the digestive lining in patients who are at high risk for ulcer development due to other necessary medications.

Eligibility and Restrictions for Use

Eligibility for Gasec (Omeprazole): Official Regulatory Profile

The eligibility for using Gasec, which contains Omeprazole, is determined by specific population rules established in official governmental regulatory documents, such as the FDA Prescribing Information and the EMA Summary of Product Characteristics.

Populations Who Must Not Use Gasec (Contraindicated)

Classification Population/Condition
Absolute Contraindication Known hypersensitivity to Omeprazole, any component of the formulation, or to substituted benzimidazoles (the drug class).
Concurrent Therapy Patients receiving rilpivirine-containing products.

Age and Condition-Based Restrictions

Use is established for adults and older adults, with no routine dose adjustment needed for the elderly or for patients with renal impairment.

Population Group Eligibility Status
Infants (< 1 year) Safety and effectiveness have not been established.
Severe Hepatic Impairment Conditional use; dose reduction should be considered.
Pregnancy/Lactation Conditional use; use requires caution and is determined by potential benefit versus risk.

What should I know about interactions with other medicines?

The official regulatory profile for Gasec documents interaction risks based on its influence on drug metabolism and gastric acidity. Co-administration is formally contraindicated with certain HIV antivirals, including Nelfinavir and Rilpivirine, due to a documented significant reduction in their plasma concentrations. This interaction may result in a loss of therapeutic effect for the co-administered drug.

The medicine acts as a moderate inhibitor of the CYP2C19 enzyme, which affects the clearance of several co-administered medicinal products. This is classified as a clinically significant pharmacokinetic interaction, notably leading to reduced exposure of the active metabolite of the antiplatelet agent Clopidogrel. It also requires monitoring for other substrates, such as Warfarin and Phenytoin, where there is a documented risk of altered systemic exposure.

Furthermore, the sustained reduction of gastric acid alters the absorption of drugs that depend on an acidic environment for uptake. This pH-dependent effect causes decreased exposure of substances like Atazanavir and the antifungals Ketoconazole and Posaconazole. Conversely, an increase in exposure is documented for drugs such as Digoxin. Specific constraints exist for high-dose Methotrexate, where delayed clearance poses a risk of toxic concentrations, and a 30-minute separation is officially noted for co-administering with Sucralfate to prevent delayed Omeprazole absorption.

Mechanism of Action

Irreversible Blockade of the Gastric Proton Pump

This mechanism involves Gasec acting as a prodrug that undergoes activation in the highly acidic environment of the parietal cell canaliculi. The resulting active compound forms an irreversible, covalent bond with the H^+/K^+-ATPase enzyme, which is the gastric proton pump. As this enzyme represents the final common step for acid secretion, its permanent deactivation effectively interrupts the body's primary acid-producing pathway.


⏳ Physiological Consequences of Sustained Acid Reduction

This permanent binding action leads to a sustained, non-competitive reduction in the enzyme's capacity to transport hydrogen ions ( H^+) into the stomach lumen. Because the inhibition is irreversible, the effect persists beyond the drug's presence in the bloodstream, lasting until new proton pump enzymes are synthesized. The physiological result is a sustained elevation of gastric pH. This systemic change reflects the altered chemical environment resulting from the reduced hydrogen ion concentration.

Dosage and Administration Information

How Gasec is Used: Official Administration Guidelines

Administration of Gasec, which contains Omeprazole, is determined by standardized protocols. The medicine is primarily intended for oral administration, typically provided as a delayed-release capsule or tablet. This gastro-resistant form is essential, requiring the capsule or tablet to be swallowed whole with fluid and not chewed, crushed, or sucked, as this would disrupt the specialized coating designed to protect the active substance from stomach acid.

Dosing Patterns and Timing

Use is generally organized around a once-daily frequency for the treatment of most acute conditions, such as duodenal ulcers and symptomatic GERD, as well as for maintenance therapy. For the majority of standard uses, a dosage of 20 mg or 40 mg once daily is specified. For conditions requiring high acid suppression, such as Zollinger-Ellison syndrome, doses can be higher and are administered in divided doses if the total daily intake exceeds 80 mg.

Consistent official guidance dictates that the medicine should be taken before eating, preferably in the morning, to optimize the timing of its action. Treatment duration is typically standardized to defined courses, such as 4 to 8 weeks for active duodenal ulcers or erosive esophagitis, while long-term use is reserved for chronic conditions like Zollinger-Ellison syndrome.

Population and Procedural Rules

Official instructions do not typically require dose adjustment for older adults or individuals with renal impairment. However, dose reduction may be needed for patients with severe hepatic impairment, where it is suggested that a maximum daily dose of 10 mg to 20 mg may suffice. If a dose is missed, the official instruction is to take it as soon as remembered unless it is near the next scheduled dose, in which case the user should skip the missed dose and not double the dose.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Gasec

This section provides a factual overview of the clinical evaluation of omeprazole (the active ingredient in Gasec), detailing the types of studies conducted, the populations included, and the specific outcomes examined by researchers, as reported in regulatory documents and peer-reviewed scientific literature.

Evidence for Use in Healing Duodenal and Gastric Ulcers

Studies examining outcomes related to duodenal and gastric ulcers primarily include Randomized Controlled Trials (RCTs) and comprehensive systematic reviews. Researchers monitored outcomes such as endoscopically confirmed ulcer closure and patient-reported outcomes describing perceived discomfort. For ulcers associated with Helicobacter pylori (H. pylori), research was conducted using Omeprazole as part of a multi-drug regimen. Short-term trials reported measurements of the rate of mucosal healing over defined time intervals.

Evidence for Erosive Esophagitis and Symptomatic GERD Trials

The evidence base for acid reflux disease was evaluated in Randomized Controlled Trials (RCTs), comparative studies, and long-term maintenance trials. Studies examined primary outcomes related to endoscopic mucosal healing (for erosive esophagitis, or EE) and monitored changes in symptoms, such as heartburn and regurgitation. Research included adult populations with symptomatic GERD, and special studies were conducted in pediatric patients (including infants) with documented EE. Findings help contextualize how patients reported their experience.

Key Limitations and Research Gaps

While a significant body of research exists, limitations are acknowledged. Sample sizes were modest for rare conditions, such as Zollinger-Ellison Syndrome (ZES), and results apply only to the highly specialized populations studied. Comparative evidence examining Omeprazole against newer drugs in the same class is continuously evolving. Certainty remains low regarding the full range of potential outcomes from use over extended durations in all patient groups, and data for certain subgroups remain insufficient.

Frequently Asked Questions (FAQ)

Common questions about Gasec (FAQ)

Q: Is Gasec the same thing as omeprazole?

Gasec is a brand name. The active substance, or main ingredient, in this medicine is omeprazole. Omeprazole is the chemical name used across all official regulatory documents.

Q: Is Gasec a short-term treatment or is it usually for long-term use?

According to official product information, the medicine is approved for defined short-term courses, typically lasting between 4 to 8 weeks, for conditions like ulcers and esophagitis. Long-term use is generally reserved for specific chronic conditions where high acid suppression is needed, such as Zollinger-Ellison syndrome.

Q: Can Gasec be taken just once in a while, or must it be taken every day?

The medicine is generally used for defined daily treatment courses for most indicated conditions. Over-the-counter (OTC) formulations are specifically indicated for daily use over a 14-day regimen for the treatment of frequent heartburn.

Q: Can taking Gasec affect the absorption of vitamins or minerals?

Regulatory information notes that prolonged treatment with this type of medicine may be associated with reduced absorption of certain nutrients, including Vitamin B12 and low blood levels of magnesium (hypomagnesemia). These concerns are typically related to long-term use.

Q: Is Gasec approved for use in children?

Official regulatory documents indicate that the medicine is approved for the treatment of Gastroesophageal Reflux Disease (GERD) and erosive esophagitis in pediatric patients. However, the safety and effectiveness have not been established in children younger than 1 year of age.

Q: Does Gasec interact with common pain relievers like ibuprofen?

Regulatory guidance notes no direct drug interaction with common non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen. Furthermore, this type of medicine is often prescribed to individuals taking NSAIDs to help reduce the risk of gastrointestinal complications.

Q: Is there a link between Gasec and increased risk of certain infections?

Official safety information notes that this medicine is associated with an increased risk of specific gastrointestinal infections, such as Clostridium difficile-associated diarrhea (CDAD). This risk is noted, particularly with extended use.

Q: Are there any known interactions between Gasec and alcohol?

Regulatory information suggests that there is no significant direct interaction between the medicine and alcohol. However, alcohol consumption may increase the production of stomach acid, which could counteract the medicine’s beneficial effects on acid suppression.

Q: Is Gasec known to cause any mental health side effects like anxiety?

Official post-marketing surveillance reports have listed psychiatric effects, including anxiety, nervousness, and depression. These types of effects are documented, though they are reported as rare or very rare adverse events.

Q: What does official guidance say about using Gasec with other stomach medications?

Official documents describe interactions with several medicines that depend on stomach acidity for absorption. Regulatory guidance describes that antacids may be used concurrently with this medicine.

Q: Is there a generic version of Gasec available?

Yes, the active ingredient in Gasec, omeprazole, is available as a generic medication approved by regulatory agencies for various uses.

Q: Do I need a prescription to get Gasec?

This medicine is available in both prescription-strength (Rx) and specific lower-strength over-the-counter (OTC) formulations. The availability depends on the dosage and the condition being treated.

Q: Can people with liver disease use Gasec?

Regulatory information notes that dose adjustments may be needed for individuals with hepatic (liver) impairment due to the altered way the drug is metabolized in the body when liver function is reduced.

Q: What research exists about Gasec use in specific populations?

Clinical trials have been conducted to establish the medicine's use in various groups. This includes specialized studies in pediatric patients and those with rare, high-acid-secreting conditions like Zollinger-Ellison Syndrome (ZES).

Q: What is the difference between prescription and over-the-counter versions of Gasec?

Prescription formulations are approved for a wider range of conditions and treatment protocols, such as ulcers and ZES. Over-the-counter (OTC) versions are indicated specifically for the short-term treatment of frequent heartburn.

Q: Are there any warnings about Gasec and skin reactions?

Regulatory documents list skin reactions such as rash, itching, and hives as common or uncommon adverse events. Severe, rare skin conditions, such as Stevens-Johnson syndrome, have also been documented in the official safety profile.

Q: Do regulatory agencies list Gasec as having any abuse potential?

Regulatory bodies assess abuse potential primarily for drugs that act on the central nervous system (CNS). This medicine is not classified as a controlled substance under the U.S. Controlled Substances Act.

Q: What are the ingredients in Gasec besides the main active component?

The full list of inactive ingredients is documented in the official regulatory product label (e.g., FDA or EMA). These typically include components necessary for the formulation, such as capsule shell materials, colorants, and excipients.

Q: Does Gasec affect my ability to drive or operate machinery?

Official guidance notes that this medicine will not usually affect a person’s ability to drive or operate machinery. However, if side effects such as dizziness or visual disturbances occur, caution is advised until those effects have fully resolved.

Q: Are older adults more likely to experience side effects from Gasec?

While dose adjustment is not typically required, regulatory safety reviews note that long-term use in older adults may be associated with increased risks compared to younger adults. These include certain risks like bone fracture and C. difficile infection.

How should Gasec be stored and disposed of?

How to Store and Dispose of Gasec?

To ensure Gasec (Omeprazole) retains its strength, store the original container at room temperature, typically between 15 C and 30 C (59 F and 86 F), and keep the container tightly sealed to protect it from moisture. The product should be kept out of the reach of children.

In-Use Stability

If preparing the oral suspension, the mixture must be used within 30 minutes and cannot be stored. Similarly, capsule contents mixed with food must be swallowed immediately and not saved for later consumption.

Disposal Requirements

The safest method for disposal is using a local drug take-back program. If this is not an option, you should mix the medicine with an unappealing substance, such as used coffee grounds or kitty litter, place the mixture in a sealed bag or container, and discard it in your household trash. Do not flush the medicine down the toilet or pour it into drains, as the substance is considered hazardous for water.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Gasec found in:

A-Z Index: